Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents

Culture-based blood-brain barrier (BBB) models are crucial tools to enable rapid screening of brain-penetrating drugs. However, reproducibility of in vitro barrier properties and permeability remain as major challenges. Here, we report that self-Assembling multicellular BBB spheroids display reprodu...

Full description

Bibliographic Details
Main Authors: Calligaris, David, Hornburg, Kalvis, Chiocca, E. Antonio, Agar, Nathalie Y. R., Lawler, Sean E., Cho, Choi-Fong, Wolfe, Justin, Fadzen, Colin M., Pentelute, Bradley L.
Other Authors: Massachusetts Institute of Technology. Department of Chemistry
Format: Article
Published: Nature Publishing Group 2018
Online Access:http://hdl.handle.net/1721.1/113429
https://orcid.org/0000-0001-9811-4396
https://orcid.org/0000-0002-1003-6045
https://orcid.org/0000-0002-4139-9578
Description
Summary:Culture-based blood-brain barrier (BBB) models are crucial tools to enable rapid screening of brain-penetrating drugs. However, reproducibility of in vitro barrier properties and permeability remain as major challenges. Here, we report that self-Assembling multicellular BBB spheroids display reproducible BBB features and functions. The spheroid core is comprised mainly of astrocytes, while brain endothelial cells and pericytes encase the surface, acting as a barrier that regulates transport of molecules. The spheroid surface exhibits high expression of tight junction proteins, VEGF-dependent permeability, efflux pump activity and receptor-mediated transcytosis of angiopep-2. In contrast, the transwell co-culture system displays comparatively low levels of BBB regulatory proteins, and is unable to discriminate between the transport of angiopep-2 and a control peptide. Finally, we have utilized the BBB spheroids to screen and identify BBB-penetrant cell-penetrating peptides (CPPs). This robust in vitro BBB model could serve as a valuable next-generation platform for expediting the development of CNS therapeutics.